There you go again banging on about trial protocols that Oncosil was NOT asked to deliver.
The trial protocols had been agreed to by both BSI and Oncosil. Oncosil was asked to deliver 20 patient supplementary data. Oncosil delivered this and much much more (42 patients were implanted) with the devise.
The data data showed the devise is clinically safe and provides significant benefits with almost 25% resection rate and significant tumour volume reduction in almost all patients.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
0.020(2.00%) |
Mkt cap ! $14.14M | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.02 | 99.5¢ | $38.97K | 38.98K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6000 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.04 | 6250 | 1 |
View Market Depth
| Last trade - 13.40pm 25/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |